Feedback / Questions
EYD-001 - EydisBio
https://www.prnewswire.com/news-releases/eydisbio-receives-fda-orphan-drug-designation-for-tak1-inhibitor-for-the-treatment-of-systemic-sclerosis-302257223.html
Sep 25, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next